2,619
Views
2
CrossRef citations to date
0
Altmetric
Cardiovascular

Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population

, ORCID Icon, , , ORCID Icon, , & show all
Pages 1051-1060 | Received 02 Jun 2022, Accepted 09 Aug 2022, Published online: 25 Aug 2022

References

  • Tang L, Gössl M, Ahmed A, et al. Contemporary reasons and clinical outcomes for patients with severe, symptomatic aortic stenosis not undergoing aortic valve replacement. Circ Cardiovasc Interv. 2018;11(12):e007220.
  • Sussell J, van Eijndhoven E, Schwartz TT, et al. Economic value of transcatheter valve replacement for inoperable aortic stenosis. Am J Manag Care. 2020;26(2):e50–6–e56.
  • Leon MB, Mack MJ, Hahn RT, PARTNER 3 Investigators, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. J Am Coll Cardiol. 2021;77(9):1149–1161.
  • Brennan MJ, Leon MB, Sheridan P, et al. Racial differences in the use of aortic valve replacement for treatment of symptomatic severe aortic valve stenosis in the transcatheter aortic valve replacement era. JAHA. 2020;9:e015879.
  • Kang G, Kim JB. Expanding transcatheter aortic valve replacement into uncharted indications. Korean J Intern Med. 2018;33(3):474–482.
  • Charlson E, Legedza ATR, Hamel MB. Decision-making and outcomes in severe symptomatic aortic stenosis. J Heart Valve Dis. 2006;15(3):10.
  • Malaisrie SC, Tuday E, Lapin B, et al. Transcatheter aortic valve implantation decreases the rate of unoperated aortic stenosis. Eur J Cardio-Thorac Surg. 2011;40(1):43–48.
  • Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791.
  • Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2021;77(4):450–500.
  • Mori M, Gupta A, Wang Y, et al. Trends in transcatheter and surgical aortic valve replacement among older adults in the United States. J Am Coll Cardiol. 2021;78(22):2161–2172.
  • Clark KA, Chouairi F, Kay B, et al. Trends in transcatheter and surgical aortic valve replacement in the United States, 2008–2018. Am Heart J. 2022;243:87–91.
  • Carroll JD, Mack MJ, Vemulapalli S, et al. STS-ACC TVT registry of transcatheter aortic valve replacement. J Am Coll Cardiol. 2020;76(21):2492–2516.
  • Reynolds MR, Magnuson EA, Lei Y, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with surgical aortic valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2012;60(25):2683–2692.
  • Reynolds MR, Magnuson EA, Wang K, PARTNER Investigators, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (cohort B). Circulation. 2012;125(9):1102–1109.
  • Baron SJ, Wang K, House JA, On behalf of the PARTNER 2 Investigators, et al. Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at intermediate risk. Results from the PARTNER 2 trial. Circulation. 2019;139(7):877–888.
  • Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363(17):1597–1607.
  • Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Cardiol. 2012;60(6):548–558.
  • Baron SJ, Thourani VH, Kodali S, et al. Effect of SAPIEN-3 transcatheter valve implantation on health status in patients with severe aortic stenosis at intermediate surgical risk: results from the PARTNER S3i trial. JACC Cardiovasc Interv. 2018;11(12):1188–1198.
  • Baron SJ, Magnuson EA, Lu M, et al. Health status after transcatheter versus surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2019;74(23):2833–2842.
  • Herrmann HC, Thourani VH, Kodali SK, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–140.
  • Kapadia SR, Leon MB, Makkar RR, et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485–2491.
  • Baron SJ, Arnold SV, Wang K, PARTNER 2 Investigators, et al. Health status benefits of transcatheter vs surgical aortic valve replacement in patients with severe aortic stenosis at intermediate surgical risk. JAMA Cardiol. 2017;2(8):837–845.
  • Heen AF, Lytvyn L, Shapiro M, et al. Patient values and preferences on valve replacement for aortic stenosis: a systematic review. Heart. 2021;107(16):1289–1295.
  • Coylewright M, Palmer R, O'Neill ES, et al. Patient‐defined goals for the treatment of severe aortic stenosis: a qualitative analysis. Health Expect. 2016;19(5):1036–1043.
  • World Health Organization. Active ageing: a policy framework [Internet]. World Health Organization; 2002 [cited 2022 Jan 19]. Report No.: WHO/NMH/NPH/02.8. Available from: https://apps.who.int/iris/handle/10665/67215.
  • Fries JF. The theory and practice of active aging. Curr Gerontol Geriatr Res. 2012;2012:420637.
  • Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2017. Natl Vital Stat Rep. 2019;68(9):1–77.
  • Gada H, Agarwal S, Marwick TH. Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: outcomes of a decision-analytic model. Ann Cardiothorac Surg. 2012;1(2):145–155.
  • University of Michigan. Health and retirement study, consumption and activities mail survey public use dataset [Internet]; 2021 [cited 2021 Oct 1]. Available from: https://hrs.isr.umich.edu/about.
  • Neumann PJ, Ganiats TG, Russell LB, et al., editors. Cost-effectiveness in health and medicine. 2nd ed. New York: Oxford University Press; 2016.
  • Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on performance measures and task force on practice guidelines. J Am Coll Cardiol. 2014;63(21):2304–2322.
  • Dharmarajan K, Foster J, Coylewright M, editors, et al. The medically managed patient with severe symptomatic aortic stenosis in the TAVR era: Patient characteristics, reasons for medical management, and quality of shared decision making at heart valve treatment centers. PLoS One. 2017;12(4):e0175926.